| The epidemiology of gastroenteropancreatic neuroendocrine tumors B Lawrence, BI Gustafsson, A Chan, B Svejda, M Kidd, IM Modlin Endocrinology and Metabolism Clinics 40 (1), 1-18, 2011 | 988 | 2011 |
| Neuroendocrine tumor epidemiology: contrasting Norway and North America O Hauso, BI Gustafsson, M Kidd, HL Waldum, I Drozdov, AKC Chan, ... Cancer 113 (10), 2655-2664, 2008 | 691 | 2008 |
| Bronchopulmonary neuroendocrine tumors BI Gustafsson, M Kidd, A Chan, MV Malfertheiner, IM Modlin Cancer 113 (1), 5-21, 2008 | 669 | 2008 |
| Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours IM Modlin, M Pavel, M Kidd, BI Gustafsson Alimentary pharmacology & therapeutics 31 (2), 169-188, 2010 | 524 | 2010 |
| Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease IM Modlin, BI Gustafsson, SF Moss, M Pavel, AV Tsolakis, M Kidd Annals of surgical oncology 17, 2427-2443, 2010 | 517 | 2010 |
| Long-term serotonin administration induces heart valve disease in rats BI Gustafsson, K Tømmerås, I Nordrum, JP Loennechen, A Brunsvik, ... Circulation 111 (12), 1517-1522, 2005 | 293 | 2005 |
| Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants M Kidd, IM Modlin, BI Gustafsson, I Drozdov, O Hauso, R Pfragner American Journal of Physiology-Gastrointestinal and Liver Physiology 295 (2 …, 2008 | 244 | 2008 |
| Neuroendocrine tumors of the diffuse neuroendocrine system BI Gustafsson, M Kidd, IM Modlin Current opinion in oncology 20 (1), 1-12, 2008 | 232 | 2008 |
| Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy KM Eltawil, BI Gustafsson, M Kidd, IM Modlin Journal of clinical gastroenterology 44 (10), 687-695, 2010 | 218 | 2010 |
| Serotonin and fluoxetine modulate bone cell function in vitro BI Gustafsson, L Thommesen, AK Stunes, K Tommeras, I Westbroek, ... Journal of cellular biochemistry 98 (1), 139-151, 2006 | 207 | 2006 |
| The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors B Lawrence, BI Gustafsson, M Kidd, M Pavel, B Svejda, IM Modlin Endocrinology and Metabolism Clinics 40 (1), 111-134, 2011 | 194 | 2011 |
| Carcinoid heart disease BI Gustafsson, O Hauso, I Drozdov, M Kidd, IM Modlin International journal of cardiology 129 (3), 318-324, 2008 | 167 | 2008 |
| IL1β‐and LPS‐induced serotonin secretion is increased in EC cells derived from Crohn’s disease M Kidd, BI Gustafsson, I Drozdov, IM Modlin Neurogastroenterology & Motility 21 (4), 439-450, 2009 | 151 | 2009 |
| Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy BI Gustafsson, L Siddique, A Chan, M Dong, I Drozdov, M Kidd, IM Modlin International journal of oncology 33 (6), 1121-1131, 2008 | 140 | 2008 |
| Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis AB Granlund, A Flatberg, AE Østvik, I Drozdov, BI Gustafsson, M Kidd, ... PloS one 8 (2), e56818, 2013 | 131 | 2013 |
| Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management IM Modlin, SF Moss, K Oberg, R Padbury, RJ Hicks, BI Gustafsson, ... Medical Journal of Australia 193 (1), 46-52, 2010 | 126 | 2010 |
| Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation AK Stunes, JE Reseland, Ø Hauso, M Kidd, K Tømmerås, HL Waldum, ... Diabetes, Obesity and Metabolism 13 (6), 551-558, 2011 | 104 | 2011 |
| Different skeletal effects of the peroxisome proliferator activated receptor (PPAR) α agonist fenofibrate and the PPARγ agonist pioglitazone U Syversen, AK Stunes, BI Gustafsson, KJ Obrant, L Nordsletten, R Berge, ... BMC endocrine disorders 9, 1-13, 2009 | 102 | 2009 |
| ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography U Plöckinger, B Gustafsson, D Ivan, W Szpak, J Davar Neuroendocrinology 90 (2), 190-193, 2009 | 98* | 2009 |
| The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in … AK Stunes, I Westbroek, BI Gustafsson, R Fossmark, JH Waarsing, ... BMC endocrine disorders 11, 1-13, 2011 | 97 | 2011 |
